Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Nishar Dipchand, a director at Seer, Inc. (NASDAQ:SEER), recently sold 30,253 shares of the company’s Class A common stock. The sale, completed on June 13, 2025, was executed under a Rule 10b5-1 trading plan, which had been adopted by Dipchand on September 4, 2024. The transaction comes as Seer’s stock has declined about 8% over the past week, though InvestingPro analysis indicates the stock is trading below its Fair Value. The shares were sold at a weighted average price of $2.0803, resulting in a total transaction value of approximately $62,935.
According to the filing, the shares were sold in multiple transactions at prices ranging from $2.055 to $2.10 per share. Following this transaction, Dipchand retains direct ownership of 49,204 shares of Seer, Inc.
In other recent news, Seer Inc . reported a notable 37% increase in revenue for the first quarter of 2025, reaching $4.2 million. Despite a net loss of $19.9 million, the company highlighted significant product innovations and strategic partnerships, including an expansion with Thermo Fisher Scientific (NYSE:TMO). Seer also introduced its new Proteograph Product Suite, aiming to enhance large-scale proteomic studies. The suite, expected to reduce analysis costs by about 60%, will be available commercially starting June 1. Analysts reacted positively, with the company maintaining its full-year revenue guidance of $17-18 million, representing a 24% growth. Seer also announced a significant project with Discovery (NASDAQ:WBD) Life Sciences involving a 10,000 sample study, marking a milestone in population-scale proteomics. The company continues to focus on expanding its user base and driving larger cohort studies. Meanwhile, Seer is actively monitoring macroeconomic factors, such as potential tariffs and government funding uncertainties, which could impact its revenue streams.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.